Background Alzheimer Management By Albumin Replacement (AMBAR) is a multicenter, randomized, placebo-controlled, Phase IIb/III clinical trial that evaluated the efficacy and safety of Plasma Exchange with replacement (PE-A) in patients mild-to-moderate Alzheimer’s disease (Boada et al., Alzheimers Dement. 2020). PE-A has demonstrated an overall benefit quality life as measured by Quality Life-A...

progressive cognitive decline is one of the hallmark symptoms of alzheimer’s disease (ad) which can be modeled by β-amyloid injection into specific regions of brain. since epigallocatechin-3-gallate (egcg) is a potent antioxidant agent which its role against oxidative stress and inflammation has been shown in prior studies, we tried to determine whether egcg administration protects against β-am...